Benjamin Edwards’s Alnylam Pharmaceuticals ALNY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$305K Buy
1,235
+67
+6% +$17K ﹤0.01% 1252
2026
Q2
$352K Buy
1,168
+83
+8% +$25K ﹤0.01% 1168
2026
Q1
$359K Buy
1,085
+352
+48% +$120K ﹤0.01% 1104
2025
Q4
$291K Buy
733
+246
+51% +$109K ﹤0.01% 1128
2025
Q3
$222K Buy
+487
New +$198K ﹤0.01% 1212

Other funds holding ALNY

Benjamin Edwards's ALNY Position: Q3 2026 in Review

Benjamin Edwards increased its Alnylam Pharmaceuticals (ALNY) stake by 5.7% in Q3 2026, buying an estimated $17K and bringing the position to 1,235 shares worth $305K. The position accounts for ﹤0.01% of the portfolio, ranked #1252.

Benjamin Edwards first reported a position in ALNY in Q3 2025 and has held it in 5 quarters since. The position peaked at $359K in Q1 2026. 591 funds tracked by Wall St. Rank hold ALNY as of Q3 2026.

  • Benjamin Edwards held 1,235 shares of Alnylam Pharmaceuticals worth $305K as of Q3 2026.
  • Benjamin Edwards bought 67 Alnylam Pharmaceuticals shares in Q3 2026, an estimated $17K.
  • Alnylam Pharmaceuticals made up ﹤0.01% of Benjamin Edwards's portfolio in Q3 2026, its #1252 holding.
  • Benjamin Edwards first reported a position in Alnylam Pharmaceuticals in Q3 2025 and has held it in 5 quarters since.
  • Benjamin Edwards's Alnylam Pharmaceuticals position peaked at $359K in Q1 2026.
  • 591 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2026.

Based on Benjamin Edwards's 13F filing for Q3 2026, filed 12 Nov 2026.